Douglas L. Jennings, PharmD, FACC, FAHA, FCCP, FHFSA, BCPS

Talking Therapeutics

Putting the I Back in the Lipid Lowering Team

10/13/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week’s issue of Talking Therapeutics, Dr Jennings highlights inclisirin, and discusses whether this novel agent holds the key to lowering residual cardiovascular risk.

In this week’s issue of Talking...

10/13/2021

Pharmacy Learning Network

Talking Therapeutics

Achieving Victory Over Venous Thromboembolism: Reviewing CHEST Guidelines

06/09/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews key points from the second update to guidelines for the treatment of venous thromboembolism.

Dr Jennings reviews key points...

06/09/2022

Pharmacy Learning Network

Talking Therapeutics

One Small Cup of Coffee for Man, One Giant Pot for Mankind?

03/27/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings walks through a new study in which researchers investigated the short-term impacts of coffee consumption on healthy adult participants.

Dr Jennings walks through a new...

03/27/2023

Pharmacy Learning Network

Talking Therapeutics

Signal for Cardiovascular Harm With Triple Inhaler Therapy

03/01/2024

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this installment of Talking Therapeutics, Dr Jennings reviews cardiovascular harm with triple inhaler therapy for patients with chronic obstructive pulmonary disorder (COPD).

In this installment of Talking...

03/01/2024

Pharmacy Learning Network

Talking Therapeutics

Blood Pressure Potpourri

04/14/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent...

When combining the high...

04/14/2021

Pharmacy Learning Network

Talking Therapeutics

DOAC Reversal and Use in Patients Recovered From COVID-19

01/05/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings reviews new research on direct oral anticoagulants in patients with COVID-19 who were discharged from the hospital, as well as real-world evidence on appropriate perioperative apixaban use.

Dr Jennings reviews new research...

01/05/2022

Pharmacy Learning Network

Talking Therapeutics

Time for a New Main Squeeze in Distributive Shock?

09/08/2022

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

In this week's Talking Therapeutics column, Dr Jennings explores the potential of angiotensin II for effectively treating patients with distributive shock.

In this week's Talking...

09/08/2022

Pharmacy Learning Network

Talking Therapeutics

Reassuring Data on Testosterone Safety

06/28/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

This week, Dr Jennings examines a new study that reviews the benefit of testosterone replacement among men with hypogonadism.

This week, Dr Jennings examines...

06/28/2023

Pharmacy Learning Network

Talking Therapeutics

Entering 2023 With Hope for Targeted Therapies

01/05/2023

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses new agents for hypertrophic obstructive cardiomyopathy and Alzheimer disease that are intended to treat underlying disease mechanisms rather than symptoms.

Dr Jennings discusses new agents...

01/05/2023

Pharmacy Learning Network

Talking Therapeutics

Targeting Triglycerides to Treat Residual CV Risk

08/04/2021

Douglas L. Jennings , PharmD, FACC, FAHA, FCCP, FHFSA, BCPS;

Dr Jennings discusses updated guidelines for the treatment of hypertriglyceridemia, recently published by the American College of Cardiology and American Heart Association, in this week’s Talking Therapeutics.

Dr Jennings discusses updated...

08/04/2021

Pharmacy Learning Network